Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) has earned a consensus recommendation of “Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $66.64.
KYMR has been the subject of a number of research analyst reports. Piper Sandler cut their target price on shares of Kymera Therapeutics from $91.00 to $43.00 and set an “overweight” rating for the company in a research report on Monday. Wells Fargo & Company assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, February 10th. They set an “overweight” rating and a $62.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, March 10th. They set a “neutral” rating and a $44.00 price objective for the company. Zacks Investment Research downgraded shares of Kymera Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Credit Suisse Group began coverage on shares of Kymera Therapeutics in a report on Thursday, April 28th. They issued an “outperform” rating and a $63.00 target price for the company.
NASDAQ:KYMR traded down $0.76 during trading hours on Tuesday, reaching $14.12. The company had a trading volume of 8,646 shares, compared to its average volume of 533,885. Kymera Therapeutics has a 52 week low of $13.64 and a 52 week high of $69.12. The firm has a market cap of $730.34 million, a price-to-earnings ratio of -5.66 and a beta of 2.20. The firm’s 50 day moving average price is $32.06 and its 200-day moving average price is $43.18.
In other Kymera Therapeutics news, Director Bvf Partners L. P/Il bought 150,000 shares of the firm’s stock in a transaction dated Thursday, May 5th. The shares were purchased at an average cost of $19.60 per share, for a total transaction of $2,940,000.00. Following the transaction, the director now owns 1,975,767 shares of the company’s stock, valued at $38,725,033.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 23.28% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Dark Forest Capital Management LP grew its holdings in Kymera Therapeutics by 3,292.0% during the 3rd quarter. Dark Forest Capital Management LP now owns 848 shares of the company’s stock valued at $50,000 after purchasing an additional 823 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new position in Kymera Therapeutics in the 3rd quarter worth about $64,000. Nisa Investment Advisors LLC grew its stake in Kymera Therapeutics by 57.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,227 shares of the company’s stock worth $52,000 after acquiring an additional 447 shares in the last quarter. Lazard Asset Management LLC bought a new position in Kymera Therapeutics in the 4th quarter worth about $78,000. Finally, Point72 Hong Kong Ltd bought a new position in Kymera Therapeutics in the 1st quarter worth about $53,000. Institutional investors own 77.73% of the company’s stock.
About Kymera Therapeutics (Get Rating)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
- Get a free copy of the StockNews.com research report on Kymera Therapeutics (KYMR)
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
- CrowdStrike: A Cybersecurity Unicorn
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.